GlassScriptPhysician profile
Daniel Nelson Kragt
NPI 1750415154
$2,506.51
in general payments reported to CMS, 2019-2025
30 companies · $803 in 2025
The $803 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.46 · 2020: $53.12 · 2021: $494 · 2022: $355 · 2023: $492 · 2024: $286 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,580.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $520.68 | 2021-2025 | |
| Insulet Corporation | $494.16 | 2021-2025 | Omnipod |
| Grifols USA, LLC | $224.61 | 2022-2025 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $193.19 | 2019-2023 | |
| Lilly USA, LLC | $189.56 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.65 | 2021-2025 | Jardiance |
| Abbott Laboratories | $100.47 | 2021-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $76.21 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $73.49 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $64.90 | 2023-2025 | |
| Tandem Diabetes Care, INC. | $42.63 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mylan Specialty L.P. | $40.91 | 2023-2024 | Yupelri |
| Medtronic, INC. | $33.05 | 2021-2024 | Inpen Smart Insulin Delivery System |
| Janssen Pharmaceuticals, INC | $31.54 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $29.29 | 2025 | Unithroid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $28.69 | 2025 | Jatenzo |
| Xeris Pharmaceuticals, INC. | $27.38 | 2021 | |
| Novo Nordisk INC | $25.70 | 2025 | Wegovy |
| Lexicon Pharmaceuticals, INC. | $25.46 | 2023 | Inpefa |
| Sequel Med Tech, LLC | $21.55 | 2025 | Twiist |
| Lundbeck LLC | $20.33 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $18.00 | 2023 | Rexulti |
| Convatec INC. | $17.16 | 2025 | |
| Philips North America LLC | $16.57 | 2024 | (Ck7) Extended Holter |
| Ibsa Pharma INC. | $15.91 | 2025 | Licart, Tirosint, Flector |
| Amgen INC. | $14.97 | 2024 | Evenity |
| Kowa Pharmaceuticals America, INC. | $14.85 | 2025 | Zoryve |
| Exact Sciences Corporation | $14.76 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $13.23 | 2023 | |
| Cequr Corporation | $9.61 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kragt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.